Segall Bryant & Hamill LLC Boosts Stake in HealthEquity, Inc. (NASDAQ:HQY)

Segall Bryant & Hamill LLC grew its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 50.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,591 shares of the company's stock after buying an additional 33,844 shares during the quarter. Segall Bryant & Hamill LLC owned 0.12% of HealthEquity worth $8,889,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Versant Capital Management Inc purchased a new position in HealthEquity in the first quarter valued at about $28,000. Transce3nd LLC purchased a new position in HealthEquity in the fourth quarter valued at approximately $29,000. Proficio Capital Partners LLC bought a new position in HealthEquity during the fourth quarter valued at $39,000. Larson Financial Group LLC increased its position in HealthEquity by 1,366.0% in the first quarter. Larson Financial Group LLC now owns 689 shares of the company's stock worth $61,000 after buying an additional 642 shares during the last quarter. Finally, Whipplewood Advisors LLC raised its stake in shares of HealthEquity by 5,060.0% in the first quarter. Whipplewood Advisors LLC now owns 774 shares of the company's stock valued at $68,000 after buying an additional 759 shares during the period. 99.55% of the stock is owned by institutional investors.

Insider Buying and Selling at HealthEquity

In other news, EVP Michael Henry Fiore sold 1,794 shares of HealthEquity stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $101.73, for a total value of $182,503.62. Following the sale, the executive vice president directly owned 53,225 shares in the company, valued at approximately $5,414,579.25. This trade represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elimelech Rosner sold 58,000 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $112.56, for a total value of $6,528,480.00. Following the transaction, the executive vice president owned 75,689 shares of the company's stock, valued at approximately $8,519,553.84. This represents a 43.38% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 291,744 shares of company stock worth $32,705,007. 1.50% of the stock is currently owned by insiders.

HealthEquity Price Performance

Shares of HQY traded down $2.42 during trading hours on Friday, reaching $97.70. 623,415 shares of the company's stock traded hands, compared to its average volume of 872,496. The firm's 50 day simple moving average is $101.65 and its 200-day simple moving average is $98.46. The stock has a market cap of $8.45 billion, a PE ratio of 37.92, a price-to-earnings-growth ratio of 1.55 and a beta of 0.49. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of 0.50. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $116.65.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. The firm had revenue of $330.80 million during the quarter, compared to analyst estimates of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same period in the previous year, the business posted $0.80 EPS. Equities analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current year.

Analysts Set New Price Targets

HQY has been the subject of several research reports. JMP Securities increased their price target on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research note on Wednesday, June 4th. Bank of America lifted their target price on shares of HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Raymond James Financial reissued a "strong-buy" rating and issued a $120.00 price target (up previously from $115.00) on shares of HealthEquity in a research report on Tuesday, July 8th. Royal Bank Of Canada raised their price objective on shares of HealthEquity from $112.00 to $117.00 and gave the stock an "outperform" rating in a report on Wednesday, June 4th. Finally, The Goldman Sachs Group boosted their target price on shares of HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a report on Wednesday, June 4th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $118.55.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.